Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • olavur
    Junior Member
    • Mar 2017
    • 2

    #1

    Spurious dosage coefficient of determination in imputed VCF file

    I have a VCF file that has dosage r^2 in the info field. The problem is that while the r^2 value should be in the 0 to 1 range, it has both negative values and values above 1.

    Is there a fundamental problem with my data? I might add that this is whole-exome data where the off-target regions have been imputed using Beagle.

    I have pasted some data collected from VCFtools, just to give an example. As you can see there are huge numbers (positive and negative), and a lot of zeros.

    Dosage r^2 example:
    CHROM POS REF ALT DR2
    1 10177 A AC 0
    1 10235 T TA 0
    1 10352 T TA 0
    1 10616 CCGCCGTTGCAAAGGCGCGCCG C 0.01
    1 10642 G A 0
    1 11008 C G 0.01
    1 11012 C G 0.01
    1 11063 T G 0


    More dosage r^2 examples:
    One allele with dr2=0, one with a huge number:
    1 66381 TATATA AATATA,T 0,5.10663e+28
    One with high correlation, another with a huge (negative) number:
    1 769829 C A,G 0.82,-7.97911e+26
    Also really tiny numbers, which is plausible, but suspicious:
    1 15274 A G,T 0,3.66383e-14

Latest Articles

Collapse

  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    Yesterday, 09:55 AM
  • SEQadmin2
    New Genomics Technologies Take Aim at Long-Standing Limits
    by SEQadmin2


    Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

    We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
    ...
    09-28-2026, 10:25 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, Today, 10:52 AM
0 responses
8 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, Yesterday, 05:39 AM
0 responses
15 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-13-2026, 09:56 AM
0 responses
15 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-09-2026, 11:14 AM
0 responses
27 views
0 reactions
Last Post SEQadmin2  
Working...